title: Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration.
authors.affiliation: Department of Emergency and Critical Care Medicine, Chiba University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ohtake
authors.forename: H
authors.initials: H
authors.lastname: Hirasawa
authors.forename: T
authors.initials: T
authors.lastname: Sugai
authors.forename: S
authors.initials: S
authors.lastname: Oda
authors.forename: H
authors.initials: H
authors.lastname: Shiga
authors.forename: K
authors.initials: K
authors.lastname: Matsuda
authors.forename: N
authors.initials: N
authors.lastname: Kitamura
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001550:Benzamidines; D006146:Guanidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006440:Hemofiltration; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006493:Heparin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D006435:Renal Dialysis
chemical_list: D000925:Anticoagulants; D001550:Benzamidines; D006146:Guanidines; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin; C032855:nafamostat